FUSED BICYCLIC HETEROCYCLIC COMPOUNDS AS CCR4 MODULATORS

CU20250028A7Pending Publication Date: 2026-06-04AURIGENE ONCOLOGY LIMITED

Patent Information

Authority / Receiving Office
CU · CU
Patent Type
Applications
Current Assignee / Owner
AURIGENE ONCOLOGY LIMITED
Filing Date
2024-05-02
Publication Date
2026-06-04
Patent Text Reader

Abstract

This disclosure provides fused bicyclic heterocyclic compounds and their derivatives of Formula (I), which are therapeutically useful as CCR4 modulators. These compounds are useful in the treatment and / or prevention of diseases and / or disorders that respond to modulation of CCR4 activity. The compounds in this disclosure are especially useful for treating cancer and inflammatory diseases and disorders. This disclosure also provides processes for preparing the compounds and pharmaceutical formulations comprising at least one of the compounds in Formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof.
Need to check novelty before this filing date? Find Prior Art